BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab
Sponsor: Cancer International Research Group (CIRG)
Listed as NCT00625898, this PHASE3 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Cancer International Research Group (CIRG), it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Oct 2020 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer International Research Group (CIRG)
- Genentech, Inc.
- Hoffmann-La Roche
- NSABP Foundation Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Adrian, United States, Akron, United States, Alba Iulia, Romania, Albany, United States, Alcorcón, Spain, Alhambra, United States, Alicante, Spain, Allentown, United States, Alliance, United States and 470 more location s